Sort by
Previous Page Page 1 of 54 Next Page
  1. Original investigation

    Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus

    A previous genome-wide association study showed that a genetic variant of sortilin was associated with the risk of coronary artery disease (CAD). However, the role of circulating sortilin is still unknown. We ...

    Tae Jung Oh, Chang Ho Ahn, Bo-Rahm Kim, Kyoung Min Kim, Jae Hoon Moon, Soo Lim, Kyong Soo Park, Cheong Lim, HakChul Jang and Sung Hee Choi

    Cardiovascular Diabetology 2017 16:92

    Published on: 20 July 2017

  2. Original investigation

    The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

    Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular o...

    Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar and Wei-Chun Huang

    Cardiovascular Diabetology 2017 16:89

    Published on: 11 July 2017

  3. Original investigation

    Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria

    To evaluate symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) as risk markers of cardiovascular disease, all-cause mortality and deterioration in renal function in a well characterised t...

    Emilie H. Zobel, Bernt Johan von Scholten, Henrik Reinhard, Frederik Persson, Tom Teerlink, Tine W. Hansen, Hans-Henrik Parving, Peter K. Jacobsen and Peter Rossing

    Cardiovascular Diabetology 2017 16:88

    Published on: 11 July 2017

  4. Original investigation

    Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia

    Omentin-1, also known as Intelectin-1 (ITLN1), is an adipokine with plasma levels associated with diabetes, obesity, and coronary artery disease. Recent studies suggest that ITLN1 can mitigate myocardial ische...

    Louis A. Saddic, Sarah M. Nicoloro, Olga T. Gupta, Michael P. Czech, Joshua Gorham, Stanton K. Shernan, Christine E. Seidman, Jon G. Seidman, Sary F. Aranki, Simon C. Body, Timothy P. Fitzgibbons and Jochen D. Muehlschlegel

    Cardiovascular Diabetology 2017 16:87

    Published on: 7 July 2017

  5. Original investigation

    Westernization of lifestyle affects quantitative and qualitative changes in adiponectin

    Although Japanese–Americans and native Japanese share the same genetic predispositions, they live different lifestyles, resulting in insulin resistance in Japanese–Americans. We investigated whether the quanti...

    Mitsunobu Kubota, Masayasu Yoneda, Norikazu Maeda, Haruya Ohno, Kenji Oki, Tohru Funahashi, Iichiro Shimomura and Noboru Hattori

    Cardiovascular Diabetology 2017 16:83

    Published on: 6 July 2017

  6. Original investigation

    Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus

    Red blood cell distribution width (RDW) is an established prognostic marker in acute and chronic heart failure (HF). Recent studies have pointed out a link among RDW, diabetes mellitus (DM) and inflammation. W...

    Andrew Xanthopoulos, Gregory Giamouzis, Andreas Melidonis, Takeshi Kitai, Efi Paraskevopoulou, Pinelopi Paraskevopoulou, Sotirios Patsilinakos, Filippos Triposkiadis and John Skoularigis

    Cardiovascular Diabetology 2017 16:81

    Published on: 6 July 2017

  7. Original investigation

    Reduced HDL function in children and young adults with type 1 diabetes

    Patients with type 1 diabetes (T1D) are at increased risk of cardiovascular disease (CVD). Measures of high-density lipoprotein (HDL) function provide a better risk estimate for future CVD events than serum le...

    Martin Heier, Mark S. Borja, Cathrine Brunborg, Ingebjørg Seljeflot, Hanna Dis Margeirsdottir, Kristian F. Hanssen, Knut Dahl-Jørgensen and Michael N. Oda

    Cardiovascular Diabetology 2017 16:85

    Published on: 6 July 2017

  8. Original investigation

    In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats

    Emerging evidence suggests that specific (poly)phenols may constitute new preventative strategies to counteract cell oxidative stress and myocardial tissue inflammation, which have a key role in the patho-phys...

    Monia Savi, Leonardo Bocchi, Pedro Mena, Margherita Dall’Asta, Alan Crozier, Furio Brighenti, Donatella Stilli and Daniele Del Rio

    Cardiovascular Diabetology 2017 16:80

    Published on: 6 July 2017

  9. Original investigation

    Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy

    To investigate the association between diabetic retinopathy (DR) and myocardial dysfunction in patients with type 2 diabetes and dilated cardiomyopathy (dCMP).

    Yoo-Ri Chung, Se-Jun Park, Ka Young Moon, Seoyoung Annie Choi, Hong-Seok Lim, Sung Wook Park, Jeong Hun Kim and Kihwang Lee

    Cardiovascular Diabetology 2017 16:82

    Published on: 6 July 2017

  10. Original investigation

    Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

    Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors can potentially reduce the risk of cardiovascular mortality in patients with type 2 diabetes mellitus (T2DM). However, there is li...

    Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino and Takahisa Hirose

    Cardiovascular Diabetology 2017 16:84

    Published on: 6 July 2017

  11. Original investigation

    α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

    Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute ph...

    Michio Shimabukuro, Atsushi Tanaka, Masataka Sata, Kazuoki Dai, Yoshisato Shibata, Yohei Inoue, Hiroki Ikenaga, Shinji Kishimoto, Kozue Ogasawara, Akira Takashima, Toshiyuki Niki, Osamu Arasaki, Koichi Oshiro, Yutaka Mori, Masaharu Ishihara and Koichi Node

    Cardiovascular Diabetology 2017 16:86

    Published on: 6 July 2017

  12. Original investigation

    Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings

    Albuminuria is an established marker for endothelial dysfunction and cardiovascular risk in diabetes and prediabetes. Exercise induced albuminuria (EiA) appears earlier and may be a more sensitive biomarker fo...

    Rafael Y. Brzezinski, Inbal Etz-Hadar, Ayelet Grupper, Michal Ehrenwald, Itzhak Shapira, David Zeltser, Shlomo Berliner, Ori Rogowski, Roy Eldor and Shani Shenhar-Tsarfaty

    Cardiovascular Diabetology 2017 16:79

    Published on: 23 June 2017

  13. Original investigation

    Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus

    Poor glycemic control is associated with impaired left ventricular (LV) diastolic function in patients with type 2 diabetes mellitus (T2DM). Inappropriate LV mass increase and accelerated aortic stiffening wer...

    Michaela Kozakova, Carmela Morizzo, Alan G. Fraser and Carlo Palombo

    Cardiovascular Diabetology 2017 16:78

    Published on: 17 June 2017

  14. Original investigation

    Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus

    Recently, basic and clinical studies have provided evidence supporting the relationship between circulating levels of fibroblast growth factor (FGF) 23 and the development of atherosclerosis. Given that diabet...

    Xingxing He, Xiang Hu, Xiaojing Ma, Hang Su, Lingwen Ying, Jiahui Peng, Xiaoping Pan, Yuqian Bao, Jian Zhou and Weiping Jia

    Cardiovascular Diabetology 2017 16:77

    Published on: 15 June 2017

  15. Review

    The regulatory role of DPP4 in atherosclerotic disease

    The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms a...

    Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan and Jixin Zhong

    Cardiovascular Diabetology 2017 16:76

    Published on: 15 June 2017

  16. Original investigation

    Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes

    Type 2 diabetes mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart patients treated by cardiac resynchronization therapy with a defibrillator (CRT-d).

    Celestino Sardu, Michelangela Barbieri, Matteo Santamaria, Valerio Giordano, Cosimo Sacra, Pasquale Paolisso, Alessandro Spirito, Raffaele Marfella, Giuseppe Paolisso and Maria Rosaria Rizzo

    Cardiovascular Diabetology 2017 16:75

    Published on: 9 June 2017

  17. Original investigation

    Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study

    We aimed to investigate the impact of diabetes duration and carotid artery stenosis (CAS) on the occurrence of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) withou...

    Minsu Noh, Hyunwook Kwon, Chang Hee Jung, Sun U. Kwon, Min Seon Kim, Woo Je Lee, Joong Yeol Park, Youngjin Han, Hyangkyoung Kim, Tae-Won Kwon and Yong-Pil Cho

    Cardiovascular Diabetology 2017 16:74

    Published on: 6 June 2017

  18. Original investigation

    The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

    In Phase 2/3 studies of basal insulin peglispro (BIL) compared to insulin glargine, patients with type 1 or type 2 diabetes previously treated with insulin and randomized to BIL had an increase in serum trigly...

    Trevor J. Orchard, Bertrand Cariou, Margery A. Connelly, James D. Otvos, Shuyu Zhang, Caryl J. Antalis, Tibor Ivanyi and Byron J. Hoogwerf

    Cardiovascular Diabetology 2017 16:73

    Published on: 6 June 2017

  19. Original investigation

    Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction

    Dipeptidyl peptidase-4 (DPP4) regulates blood glucose levels and inflammation, and it is also implicated in the pathophysiological process of myocardial infarction (MI). Plasma DPP4 activity (DPP4a) may provid...

    Jing-Wei Li, Yun-Dai Chen, Wei-Ren Chen, Qi You, Bo Li, Hao Zhou, Ying Zhang and Tian-Wen Han

    Cardiovascular Diabetology 2017 16:72

    Published on: 6 June 2017

  20. Review

    Platelets, diabetes and myocardial ischemia/reperfusion injury

    Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet f...

    Isabella Russo, Claudia Penna, Tiziana Musso, Jasmin Popara, Giuseppe Alloatti, Franco Cavalot and Pasquale Pagliaro

    Cardiovascular Diabetology 2017 16:71

    Published on: 31 May 2017

  21. Study protocol

    Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

    Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density ...

    Dirk Müller-Wieland, Lawrence A. Leiter, Bertrand Cariou, Alexia Letierce, Helen M. Colhoun, Stefano Del Prato, Robert R. Henry, Francisco J. Tinahones, Lisa Aurand, Jaman Maroni, Kausik K. Ray and Maja Bujas-Bobanovic

    Cardiovascular Diabetology 2017 16:70

    Published on: 25 May 2017

  22. Original investigation

    The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

    Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic ef...

    Arwa Younis, Dana Eskenazi, Ronen Goldkorn, Jonathan Leor, Nili Naftali-Shani, Enrique Z. Fisman, Alexander Tenenbaum, Ilan Goldenberg and Robert Klempfner

    Cardiovascular Diabetology 2017 16:69

    Published on: 22 May 2017

  23. Original investigation

    Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

    Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist adminis...

    Weena J. Y. Chen, Michaela Diamant, Karin de Boer, Hendrik J. Harms, Lourens F. H. J. Robbers, Albert C. van Rossum, Mark H. H. Kramer, Adriaan A. Lammertsma and Paul Knaapen

    Cardiovascular Diabetology 2017 16:67

    Published on: 19 May 2017

Previous Page Page 1 of 54 Next Page